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Hydrogels are three dimensional, crosslinked networks of hydrophilic polymers 
swollen with a large amount of water or biological fluids. Dextrin, a low-molecular-
weight carbohydrate composed by glucose residues, has been used to develop a novel 
fully resorbable and injectable hydrogel for biomedical applications. Dextrin was firstly 
oxidized (ODEX) to introduce aldehyde groups which then reticulate with adipic acid 
dihydrazide (ADH), forming the dextrin-based hydrogel (HG) [1]. The cross-linked 
ODEX is an in situ forming hydrogel, which displays a three-dimensional network with 
inter-connective pores, and is able to incorporate nanogels, cells and biomolecules for 
biomedical applications [1-3].  
Genotoxicity is an important endpoint in the safety assessment of polymeric-based 
medical devices. ISO 10993-3 (2014) recommends a battery of in vitro genotoxicity 
tests employing eukaryotic and prokaryotic models to determine the potential to 
induce gene mutations, changes in chromosome structure and number, and other 
DNA or gene abnormalities caused by the medical devices [4]. Thus, in this study 
AMES, cytokinesis-block micronucleus (CBMN) and comet assays were used to assess 
the genotoxic potential of the HG and its isolated components (ODEX and ADH). The 
results revealed that HG, as well as, ODEX and ADH did not induce significant DNA and 
chromosomal damage, demonstrating the genocompatibility of the HG for biomedical 
applications.  
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